To assess the ability of soluble SNIPRs to improve the therapeutic window of CARs that are prone to off-tumour toxicity, we replaced the human-specific 4D5 HER2 CAR with a previously described mouse–human cross-reactive DARPin-based variant33. The gene discussed is ERBB2; the disease is neoplasm.